The MAX Study: A randomised phase II/III study to determine the relative toxicity of Mitomycin C, Avastin and X eloda in patients with untreated metastatic colorectal cancer, and to compare the effects of Mitomycin C, Avastin and Xeloda in patients with untreated metastatic colorectal cancer on progression-free survival.

Trial Profile

The MAX Study: A randomised phase II/III study to determine the relative toxicity of Mitomycin C, Avastin and X eloda in patients with untreated metastatic colorectal cancer, and to compare the effects of Mitomycin C, Avastin and Xeloda in patients with untreated metastatic colorectal cancer on progression-free survival.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Mitomycin
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MAX
  • Most Recent Events

    • 03 Jun 2014 Results of the predictive/prognostic impact of SNP genotype presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 30 May 2014 Results on predictive impact of gene mutation status presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 18 Jan 2014 Results of an analysis in 196 patients who underwent a biomarker analysis presented at the 2014 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top